We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Outline
- Mechanisms involved in pulmonary arterial hypertension (PAH)
- Lung explant histology: PAH, grade 4 (Heath and Edwards)
- Severe RV failure in IPAH
- World Symposium on PH (2024): PH classification (5 Dx groups)
- WSPH 2018, 2024: New hemodynamic definitions of pediatric PH
- Quote from Lewis Rubin
- PH in childhood: frequently asked questions by parents
- Published review of PH in infants, children and young adults
- Common differences in the etiologies of pediatric and adult pulmonary hypertension
- Most common etiologies (causes) of PH in childhood
- Heritable PAH: relative contribution of known risk genes and de novo mutations
- Algorithm on genetic testing and counseling
- Consensus treatment on how to diagnose and treat pediatric PH
- Diagnostic algorithm (pediatric PH)
- Pulmonary hypertension in infancy (groups 1+3 PH)
- Management of PPHN
- Pulmonary hypertension in infancy (groups 1+3 PH)
- PH risk stratification (adults, children)
- Risk stratification tools have been lacking for pediatric PH
- The 2022 adult PAH 3-strata risk assessment model
- The 2022 adult PAH simplified 4-strata risk assessment model
- LuTx-free survival in adult PAH according to risk (4-strata risk assessment model)
- Adult PAH treatment algorithm (WSPH 2024) (according to 4-strata risk assessment model)
- Sotatercept: likely a game changer for PAH therapy
- Sotatercept is an investigational, potential first-in-class activin signaling inhibitor
- MOONBEAM: Study design overview (pediatric PAH)
- MOONBEAM: key inclusion and exclusion criteria
- Determinants of risk in PH
- Risk stratification for pediatric PAH (2-strata; WSPH 2024)
- The 2019 EPPVDN pediatric PH risk score
- Cardiac MR predicts clinical worsening and mortality in PAH
- Validation of risk score by CMR and echo in pediatric PAH
- Strong correlations of the risk scores with outcome-relevant imaging variables
- Strong correlations of the EPPVDN risk score with outcome relevant CMR imaging variables
- The EPPVDN PH online risk score calculator
- Advanced treatment of PAH in childhood
- VISION of reverse-remodeling therapies in PAH / PHVD
- PAH pharmacotherapy
- Targeted PAH medications and their approval by regulatory agencies
- Treatment algorithm (EPPVDN 2019)
- Macitentan: a modified, non-selective endothelin-1 receptor antagonist
- Safety and efficacy of add-on macitentan in pediatric PH
- Oral and parenteral (inhal., s.c./i.v.) prostacyclin (analogue) therapy of PAH
- Selexipag
- Selexipag in pediatric PH: improvement in 50%, stabil. 20-25%, detoriation in 20-25%
- PAH associated with congenital heart diseases (PAH-CHD)
- Hemodynamics with large VSD
- Management of PAH-CHD
- Conclusions: PH therapy - recent developments
- Vasodilator response in PAH - good/poor, sustained/transient
- Oral selexipag vs. continuous parenteral PCA therapy (S.C./I.V.)
- OMT Lenus pro subcutaneously implanted, intravenous treprostinil pump
- 2019 updated consensus statement
- New emerging therapies
- Off-label, compassionate use study
- Mechanical circulatory support in acute cardipulmonary failure and lung transplantation for End-stage PAH
- VA-ECMO in infants with cardiopulmonary failure
- Endstage IPAH patient
- Pediatric lung transplantation: Hannover (GER) - survival 2
- LuTx for pediatric PAH at Hannover Medical School
- LuTx for pediatric PAH: demographic data
- 9 of 15 patients were higher risk (non-invasive) at the time of LuTx
- Peri-op management of PAH patients undergoing lung transplantation (LuTx)
- Full recovery of RV systolic function and RV volumes 2 months after LuTx (echocardiography)
- Recovery of RV function after pressure unloading s/p LuTx (cardiac MRI)
- Full recovery of RV systolic function and RV volumes 2 months after LuTx (cardiac MRI) (1)
- Full recovery of RV systolic function and RV volumes 2 months after LuTx (cardiac MRI) (1)
- Conclusions: LuTx for pediatric PAH
- Outcome data (international Potts shunt registry)
- Changes and future directions of clinical research in pediatric PH
- EPPVDN consensus statements in development 2025-2026
Topics Covered
- Pulmonary arterial hypertension (PAH)
- PH in childhood
- Etiologies of pediatric and adult pulmonary hypertension
- Diagnostic algorithm
- Risk stratification
- Determinants of risk in PH
- Pediatric PH risk score
- Pharmacotherapy
- Management of PAH
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Hansmann, G. (2025, July 31). Pulmonary arterial hypertension in infants, children and young adults [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 24, 2025, from https://doi.org/10.69645/EZRF6582.Export Citation (RIS)
Publication History
- Published on July 31, 2025
Financial Disclosures
- Dr. Hansmann is the Chair, Leadership Board Member and Writing Group Chair of the European Pediatric Pulmonary Disease Network. He is the Founding Chair and subsequent Councillor (2015-2021) of the Working Group “Pulmonary Hypertension, Heart Failure, and Transplantation“ (PHHFTX). He is a writing group member of the Consensus Statement on PH-LHD, AHA and Consensus Statement on Periop. PH, ISHLT. He was a Co-Chair, AHA/ATS Guidelines on Pediatric Pulmonary Hypertension. He is a Task Force Member, ESC/ERS Guideline on Pulmonary Hypertension. He has received educational grants from Janssen/J&J, Bayer, Merck/MSD, Optimed and OrphaCare. He has a a European + International Patent Application related to HUCMSC-CM treatment of chronic heart-lung and vascular diseases (EP22177263.5; PCT/EP2023/064627).
Pulmonary arterial hypertension in infants, children and young adults
Published on July 31, 2025
49 min
A selection of talks on Physiology & Anatomy
Transcript
Please wait while the transcript is being prepared...
0:00
This talk is about
Pulmonary Arterial
Hypertension in
infants, children,
and young adults.
My name is Georg Hansmann.
I'm a Professor of Pediatrics
in Pediatric Cardiology at
the Friedrich Alexander
University in
Erlangen-Nuremberg,
Bavaria, Germany.
I'm also the Founding Chair of
the European Pediatric Pulmonary
Vascular Disease Network.
0:22
These are my disclosures.
0:26
Here's the outline,
you can have a look at it,
but we won't go through it.
0:31
The mechanisms involved in
pulmonary arterial
hypertension include,
at the beginning, endothelial
dysfunction and apoptosis,
pulmonary arterial smooth
muscle cell proliferation,
inflammation, and fibrosis.
That leads then to
vascular remodeling,
peripheral PA
obliteration and also
pulmonary artery loss
in the periphery.
Followed by increased
vascular resistance and
pulmonary arterial hypertension.
Over time, that results in
right ventricular
dysfunction due to
the pressure overload
of the right ventricle.
As you can see here
with the arrow,
the interventricular septum
bulges into the left ventricle.
There is LV compression
and underfilling,
and ultimately, heart
failure and death.
1:17
Here you see the histology of
a grade 4 advanced
PAH patient who
underwent lung transplantation.
You see concentric lesions,
also plexiform lesions,
even remodeling of
the airways and
also fresh intra-alveolar
hemorrhage.
1:39
This is an echocardiography.
On the left upper corner
four-chamber view,
you see the small
left ventricle and
the interventricular
septum being,
in end-systole, convexed
to the left side.
In the upper middle,
there is vector
velocity imaging.
In the right upper corner,
there is a short axis view
in echocardiography where
you can see the
typical features:
dilated hypertrophic
right ventricle,
a D-shape of the left ventricle,
and there is
pericardial effusion.
In the right lower corner,
there's a cardiac MRI image.
It showed excess fill of
the patient's right
ventricle prior to
lung transplantation—a huge
right ventricle, dilated.
Again, there is a D-sign and
underfilling and compression
of the left ventricle
as well as pericardial effusion.
In the left lower corner,
there is a typical estimation:
a right ventricular
systolic pressure by
Doppler echocardiography.
Hide